{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:20:50Z","timestamp":1771042850759,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.amjcard.2020.12.017","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T22:46:29Z","timestamp":1615243589000},"page":"S32-S39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation"],"prefix":"10.1016","volume":"144","author":[{"given":"Christopher P.","family":"Cannon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.12.017_bib0001","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0002","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0003","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.amjcard.2020.12.017_bib0004","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.amjcard.2020.12.017_bib0005","first-page":"527","article-title":"Final results","volume":"84","year":"1991","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2020.12.017_bib0006","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study","volume":"343","year":"1994","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0007","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A Clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0008","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2020.12.017_bib0009","first-page":"204","article-title":"Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: a systematic review and meta-analysis","volume":"29","author":"Andrade","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.amjcard.2011.10.046","volume":"109","author":"Nikolsky","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0011","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ahj.2012.01.018","article-title":"Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?","volume":"163","author":"Verheugt","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0012","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0013","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0014","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jacc.2011.07.021","article-title":"Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial","volume":"58","author":"Suh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0015","first-page":"631","article-title":"Atrial fibrillation patients do not benefit from acetylsalicylic acid. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol","volume":"16","author":"Sj\u00e4lander","year":"2014","journal-title":"Eur Soc Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0016","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nrcardio.2011.112","article-title":"The role of aspirin for stroke prevention in atrial fibrillation","volume":"8","author":"Lip","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0017","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0018","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0019","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0020","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0021","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.jcin.2019.07.059","article-title":"Dabigatran dual therapy versus warfarin triple therapy post-PCI in patients with atrial fibrillation and diabetes","volume":"12","author":"Maeng","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0022","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.amjcard.2019.11.029","volume":"125","author":"Ten Berg","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008349","article-title":"Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: a subgroup analysis from the REDUAL PCI trial","volume":"13","author":"Berry","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0024","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2019.02.006","article-title":"Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: an ancillary analysis from the RE-DUAL PCI trial","volume":"212","author":"Lip","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0025","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0026","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","article-title":"Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS Trial","volume":"141","author":"Lopes","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0027","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008465","article-title":"Novel oral anticoagulants following percutaneous coronary intervention","volume":"13","author":"Abadie","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0029","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0030","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.08.21","article-title":"From WOEST to AUGUSTUS: a review of safety and efficacy of triple versus dual antithrombotic regimens in patients with atrial fibrillation requiring percutaneous coronary intervention for acute coronary syndrome","volume":"7","author":"Jones","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0031","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017212","article-title":"Safety and efficacy of double antithrombotic therapy with non\u2013vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"9","author":"Capodanno","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0032","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0033","doi-asserted-by":"crossref","first-page":"B24","DOI":"10.1016\/j.jacc.2020.09.032","article-title":"TCT CONNECT-58 evaluation of antithrombotic strategies before and after the first month of therapy: landmark analysis of the RE-DUAL PCI Trial","volume":"76","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0034","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple Therapy in patients requiring oral anticoagulation after drug-eluting stent implantation","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0035","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0036","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0038","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.12.017_bib0039","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920313448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920313448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:36:41Z","timestamp":1757572601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920313448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"alternative-id":["S0002914920313448"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.017","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}